Investment Stage

Focus Areas

About Investor

Myla Lai-Goldman serves as a Venture Partner at Hatteras Venture Partners, focusing on investments in health IT, health & hospital services, diagnostics, and digital health sectors. She typically invests at the seed and Series A stages with an investment range of $100K - $5.0M. Lai-Goldman has over 25 years' experience in the development, commercialization, and adoption of novel molecular diagnostic assays. In 2011, she co-founded GeneCentric Therapeutics, a Hatteras Fund III company leveraging deep RNA expertise to develop the Cancer Subtype Platform. Until her retirement in 2008, she was Executive Vice President, Chief Medical Officer of LabCorp®, where she managed all quality, science, and medical activities for the company and its subsidiaries. She earned an MD from Columbia University and completed postgraduate training in Internal Medicine, anatomic and clinical pathology, and hematopathology.